A Multicentre Prospective Phase II Single Arm Trial Evaluating the Benefit of Therapy With Lenalidomide (Revlimid) in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type) After First Line Treatment by Chemotherapy Plus Rituximab for the French Study Group of Cutaneous Lymphoma (GFELC)

Trial Profile

A Multicentre Prospective Phase II Single Arm Trial Evaluating the Benefit of Therapy With Lenalidomide (Revlimid) in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type) After First Line Treatment by Chemotherapy Plus Rituximab for the French Study Group of Cutaneous Lymphoma (GFELC)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Cutaneous B-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms REV-LEG
  • Most Recent Events

    • 28 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 15 Oct 2012 Planned end date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
    • 23 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top